Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GlycoMimetics, Inc. - Common Stock (NQ:GLYC)

0.2480 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GlycoMimetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket
Shares of Trinity Place Holdings Inc. (NYSE: TPHS) rose sharply in pre-market trading. The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan.... 
Via Benzinga
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
From Apollomics Inc.
Via GlobeNewswire
Earnings Outlook For GlycoMimetics
Via Benzinga
GlycoMimetics: Q1 Earnings Insights
Via Benzinga
Earnings Preview For GlycoMimetics
Via Benzinga
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
From GlycoMimetics, Inc.
Via Business Wire
Earnings Scheduled For November 3, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope... 
Via Talk Markets
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
From GlycoMimetics, Inc.
Via Business Wire
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million. 
Via Benzinga
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
From GlycoMimetics, Inc.
Via Business Wire
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of... 
Via Benzinga
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
$3M Bet On This Biotechnology Stock? Check Out These 3 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.